KCT0008295招募中Unknown
A randomized phase II study of LAZErtiNib alone versus Lazertinib plus bevaCizumab for Advanced non-small cell lung cancer with epidermal growth factor receptor activating mutations and smoking history
ational Cancer Center0 个研究点目标入组 120 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Histologically confirmed patients with locally progressive or metastatic non-small cell lung cancer (IIIB or IV) who have not been diagnosed as squamous cell carcinoma.
- •2) Patients with one or more measurable lesions in accordance with the RECIST criteria (Version 1.1), tumor lesions located at the previous irradiation site, are considered measurable if progress has been made in those lesions.
- •3) Patients with institutionalized EGFR mutation (exon 19 deletion or L858R)
- •4) Patients with a history of smoking, including those who are currently smoking (defined as those who have smoked more than 100 cigarettes in their lifetime)
- •5) ECOG PS 0-1 Patient
- •6) Patients with appropriate hematological functions
- •ANC=1,500/uL, hemoglobin=9.0g/dL, platelet=100,000/uL
- •7) Patients with adequate liver function
- •Total bilirubin < 1 x UNL, AST (SGOT) and ALT (SGPT) < 2.5 x UNL
- •(If there is an interruption: total bilirubin <3 x UNL, AST (SGOT) and ALT (SGPT) <5 x UNL)
- •8) a patient with appropriate renal function
- •Cr UN UNL, however, can be registered if the creatinine clearance calculated according to the formula Cocroft and Gault is 50 50 ml/min outside the normal range.
- •Proteinuria test <2+ (if 22+ then protein 11g must be in 24-hour urine test)
- •9) Patients with a history of receiving radiation therapy must meet the following criteria.
- •- In the case of direct radiation irradiation to the lung lesion area, it must have elapsed at least 12 weeks from the time of registration.
- •- In the case of chronic radiation therapy for intracoracic bone metastasis, it must be at least 12 weeks from the time of registration.
- •- 2 weeks or more from the time of registration if radiotherapy has been performed on any non-chest area
- •Must be elapsed.
- •10) At the time of registration, the date of completion of the previous treatment or procedure must pass the period specified below.
- •- Surgery (including exploratory/experimental thoracotomy): 4 weeks
- •- Pericardial drainage: 1 week
- •- pleural adhesion not attributed to anti-species positive substances (including biological response regulators such as Picibanil): 2 weeks
- •- Tissue biopsy to confirm selection criteria (including biopsy using thoracoscope): 1 week
- •- Procedures for the treatment of trauma (unregistered patients with untreated wounds): 2 weeks
- •- Blood transfusion, hematopoietic growth factor administration: 2 weeks
- •- The puncture and aspiration cell test: 1 week
- •- Administration of other clinical trial medications: 4 weeks
- •11) Women in childbearing age should be negative in serum or urine pregnancy tests within 7 days prior to test treatment.
- •12) Male and childbearing female test subjects with female partners' pregnancy must agree to use the following two high-efficiency test methods for at least 180 days after the last dose of the assigned treatment is administered. Bevacizumab can also damage a woman's reproductive ability. Therefore, women who have entered the bevacizumab combination group should be preceded by discussions on preserving the reproductive ability of women who are likely to become pregnant before treatment
- •- asceticism
- •- tubal ligation
- •- Hormone contraceptives that do not cause drug interactions (such as Mirena)
- •- Medroxyprogesterone injection (Depo-Provera)
- •- Copper bands and intrauterine devices
- •- a partner's vasectomy
- •- Partner's use of condoms
- •13) Patients who have agreed to the clinical trial
排除标准
- •1) Patients with other malignant tumors except lung cancer within the past three years (except for properly treated cervical epithelial cancer, basal or squamous cell skin cancer, thyroid cancer, and topical prostate cancer surgically treated for healing purposes).
- •2) Patients with a history of bleeding above Grade 2 (with blood above Grade 2) 2.5mL within 3 months of registration
- •defined as the above bright red blood.)
- •3) chemotherapy for advanced lung cancer in the past or other systemic anticancer drugs (single-clone antibodies or
- •Patients with tyrosine kinase inhibitors)
- •(However, pre- and post-operative assisted chemotherapy, which ended 6 months before the time of registration, is allowed.)
- •4) A patient with evidence of invasion of large blood vessels, such as the pulmonary artery or relative vein of a tumor, in contrast examination.
- •5) Patients scheduled to undergo hydrophobic surgery (including infantile catheter insertion) within 24 hours of the first injection of bevacizumab
- •6) Current or recent (within 10 days prior to the initial injection of bevacizumab) aspirin (>325 mg/day) and patients with oral or injectable anticoagulants or thrombolytic agents for therapeutic purposes (provided that preventive use of anticoagulants is permitted).)
- •7) Patients currently in use (or unable to discontinue prior to the initial dose of lazertinib) with a drug or natural aid known as a potent CYP3A4 inducer that cannot be discontinued throughout clinical trials before enrollment
- •8) Any evidence of ILD, drug-induced ILD, past history of radiation interstitial pneumonia requiring steroid treatment, or clinically active ILD
- •9) Patients undergoing or likely to administer bisphosphonate medication
- •10) Uncontrolled patients with brain-spinal metastasis (Patients with epilepsy can be registered if they are stabilized asymptomaticly, and treated patients with epilepsy can be registered if they do not currently require steroid treatment.)
- •11) Patients with clinically significant ophthalmic abnormalities on the surface of the eye (not recommended to use contact lenses) (with corneal perforations or ulcers, symptoms and signs of acute or exacerbated corneal inflammation such as ocular inflammation, tear secretion, blurred vision, eye pain and bleeding)
- •12) Patients with a history of coagulopathy with hereditary bleeding constitution or risk of bleeding
- •13) Patients with uncontrolled hypertension (systolic blood pressure >150 mmHg and/or diastolic >100 mmHg)
- •14) Patients with clinically significant active cardiovascular disease (within 6 months of registration, patients with cerebrovascular accidents and diseases, myocardial infarction, unstable angina, NYHA ClassIIII congestive heart failure, thrombosis, thromboembolism, and severe cardiac arrhythmia that may interfere with drug administration during clinical trials)
- •The following heart criteria are not limited to one. :
- •Average of corrected QT intervals at rest (QTc intervals corrected by Fredericia formula) >470 msec based on QTc values calculated by ECG equipment by the test institution during screening.
- •clinically significant abnormal findings found in the rhythm, conduction, or morphology of the ECG at rest (e.g., complete left block, 3rd degree heart block, 2nd degree heart block)
- •All factors that increase the risk of QTc prolongation or arrhythmia, including heart failure, hypokalemia, family history of congenital QT prolongation syndrome, sudden death of causes under t
研究者
相似试验
招募中
不适用
A Study of Lazertinib as Consolidation Therapy in Patients with Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) following Chemoradiation TherapyKCT0007226Koera University Guro Hospital77
尚未招募
Unknown
A randomized, phase 2 trial of lazertinib and chemotherapy combination in EGFR-mutant NSCLC patients without ctDNA clearance after lead-in lazertinib monotherapy (CHAMELEON)NeoplasmsKCT0008774Yonsei University Health System, Severance Hospital129
进行中（未招募）
1 期
Randomised Controlled Trial of Lapatinib (A Her1/2 Tyrosine Kinase Inhibitor) on Epithelial Proliferation and Apoptosis in Ductal Cancer in Situ. - Pre-operative study of Lapatanib in DCISWomen with a core biopsy diagnosis of histologically proven Her2 positive DCIS (or DCIS and invasive cancer). Women undergoing re-excision of DCIS will be eligible provided residual DCIS is present in the re-excision specimen.MedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2006-006619-64-GBniversity Hospital of South Manchester NHS Foundation Trust80
尚未招募
不适用
Phase II Trial of Lazertinib in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Metastatic Non-Small Cell Lung Cancer with Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR Tyrosine Kinase InhibitorKCT0006207The Catholic University of Korea, Seoul St. Mary's Hospital40
已完成
2 期
A randomized phase II study of Erlotinib with or without Bevacizumab in NSCLC patients previouly treated with platinum-based chemotherapy containing bevacizumab. North Japan Lung Cancer Study Group Trial 1201JPRN-UMIN000007475orth Japan Lung Cancer Study Group64